![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Health Canada Grants Priority Review for Heron’s Non-Opioid Pain Treatment
Health Canada Grants Priority Review for Heron’s Non-Opioid Pain Treatment
![Heron Therapeutics Logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/HeronTherapeutics_Logo.gif?t=1576446934&width=430)
December 13, 2019
Heron Therapeutics received a priority review from Health Canada for its non-opioid postoperative pain treatment HTX-011.
HTX-011 is a fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam. In phase 3 studies, it significantly reduced pain and opioid use compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control.
Heron filed an NDA for the drug after receiving a complete response letter for its previous NDA in August. The FDA is expected to approve the drug in March 2020.
Upcoming Events
-
21Oct